CD8A and neoplasm: The inhibition of CD38 expression on tumor cells reduces adenosine production and improves the efficacy of immune checkpoint therapy, demonstrating greater accumulation of CD8+ T cells and lower levels of Treg cells in mouse tumor models (138, 139).